Journal of Parkinsons Disease

Papers
(The H4-Index of Journal of Parkinsons Disease is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
The Impact of the COVID-19 Pandemic on Parkinson’s Disease: Hidden Sorrows and Emerging Opportunities215
The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease99
The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease93
Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects87
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 202086
The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson’s Disease82
The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline77
Barriers and Motivators to Engage in Exercise for Persons with Parkinson’s Disease67
Care, Convenience, Comfort, Confidentiality, and Contagion: The 5 C’s that Will Shape the Future of Telemedicine65
Parkinson’s Disease and the COVID-19 Pandemic63
Young Onset Parkinson’s Disease: A Modern and Tailored Approach62
GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop61
Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations55
Infection and Risk of Parkinson’s Disease53
LRRK2 and the Endolysosomal System in Parkinson’s Disease48
Parkinsonism as a Third Wave of the COVID-19 Pandemic?47
Body-Worn Sensors for Remote Monitoring of Parkinson’s Disease Motor Symptoms: Vision, State of the Art, and Challenges Ahead46
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update45
Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson’s Disease43
Deep Phenotyping of Parkinson’s Disease42
Preventing Parkinson’s Disease: An Environmental Agenda41
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update41
Systematic Review Looking at the Use of Technology to Measure Free-Living Symptom and Activity Outcomes in Parkinson’s Disease in the Home or a Home-like Environment40
Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk40
Digital Biomarkers of Mobility in Parkinson’s Disease During Daily Living39
The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease38
Management of Pain in Parkinson’s Disease36
Vagus Nerve and Stomach Synucleinopathy in Parkinson’s Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the “Body-First” Hypothesis35
An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 Cohorts35
Global Perspective on Telemedicine for Parkinson’s Disease35
Recommendations for Deep Brain Stimulation Device Management During a Pandemic34
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future33
People with Parkinson’s Disease: What Symptoms Do They Most Want to Improve and How Does This Change with Disease Duration?33
0.057172775268555